July 17, 2023 — A recent thread in the ongoing public discourse about new, advanced obesity medicines relates to how long people should take them and how long they actually do take them. The revelation that started this is data from a pharmacy benefit manager (PBM) indicating that two-thirds of patients typically stop taking them within a year. So […]
May 12, 2023 — Don’t look at me! That’s basically how it went at a U.S. Senate hearing Wednesday. Top executives from PBMs (pharmacy benefit managers) and the three pharma companies selling insulin testified to suggest they’re doing everything they possibly can to keep drug prices low. PBMs point the finger at pharma. Pharma executives return the favor. Lilly […]
January 15, 2023 — Workers at the largest health system in the U.S., HCA, this week accused the system of putting profits ahead of patient care and health. We regularly hear from obesity care providers about insurers using lame excuses to deny coverage for obesity meds or surgery for lame reasons. This happens even when the health plan covers […]
May 24, 2022 — Drug pricing has been getting a lot of attention for some time now, so it’s no surprise that the prices of obesity medicines would get attention, too. New medicines are coming, competition will be increasing, and one factor in that competition will be prices. The only way to get good value is to consider both […]
